Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Regenxbio Inc shares valued at $262,635 were sold by Simpson Curran on Oct 09 ’25. At $12.62 per share, Simpson Curran sold 20,811 shares. The insider’s holdings dropped to 216,162 shares worth approximately $2.66 million following the completion of this transaction.
Also, CURRAN M SIMPSON purchased 20,811 shares, netting a total of over 254,310 in proceeds.
Before that, Simpson Curran had sold 7,624 shares from its account. In a trade valued at $76,469, the Chief Executive Officer traded Regenxbio Inc shares for $10.03 each. Upon closing the transaction, the insider’s holdings decreased to 7,624 shares, worth approximately $2.91 million.
As published in a research note from Goldman on February 11, 2025, Regenxbio Inc [RGNX] has been rated down from a Buy to a Neutral and the price target has been revised to $14 from $38.
Analyzing RGNX Stock Performance
On last trading session, Regenxbio Inc [NASDAQ: RGNX] rose 9.33% to $12.3. The stock’s lowest price that day was $11.34, but it reached a high of $12.345 in the same session. During the last five days, there has been a surge of approximately 0.65%. Over the course of the year, Regenxbio Inc shares have jumped approximately 24.37%.
Is Regenxbio Inc subject to short interest?
Stocks of Regenxbio Inc saw a sharp steep in short interest on 2025-09-30 dropping by -0.15 million shares to 4.98 million. Data from Yahoo Finance shows that the short interest on 2025-08-29 was 5.14 million shares. A decline of -3.02% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 10.22 of the overall float, the days-to-cover ratio (short ratio) decline to 10.22.
Which companies own the most shares of Regenxbio Inc (RGNX)?
In terms of Regenxbio Inc share price expectations, FactSet research, analysts set an average price target of 30 in the next 12 months, up nearly 166.67% from the previous closing price of $11.25. Analysts anticipate Regenxbio Inc stock to reach 40 by 2025, with the lowest price target being 18. In spite of this, 6 analysts ranked Regenxbio Inc stock as Buy at the end of 2025. On June 07, 2024, Goldman assigned a price target of “a Buy” to the stock and initiated coverage with a $38.
